Development of polymyxin B derivatives incorporating uncommon amino acids: synthesis and antimicrobial activity

dc.commentsCEB58470
dc.contributor.authorLinhares, Mariana Esteves
dc.contributor.authorCosta, Susana Paula
dc.contributor.authorLopes, Susana Patrícia
dc.date.accessioned2025-11-19T16:18:46Z
dc.date.issued2025
dc.date.updated2025-09-07T12:24:14Z
dc.description.abstractThe alarming rise of antimicrobial resistance (AMR) and multidrug-resistant (MDR) Gram-negative bacteria led the World Health Organization (WHO) to publish a list of pathogens for which the development of new antibiotics is urgent. Some bacteria have been prioritized as they are resistant to more than three classes of antibiotics, such as the ESKAPE group that includes Gram-positive bacteria (Enterococcus faecium, Staphylococcus aureus) and Gram-negative bacteria (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). In addition to multiresistance, they present increasing levels of virulence, which make these bacteria essentially responsible for infections in hospital environments [1,2]. The dry antibiotic pipeline is not able to keep pace to address this problem, and polymyxins (PMs) have recently been rehabilitated as last-resort drugs against MDR Gram-negative bacteria. Regrettably, besides the well-documented side effects (nephro- and neurotoxicity), resistance has also emerged in response to their increased use [3]. This has triggered the search for new PM derivatives with improved activity and reduced toxicity. However, the study of a large number of modified PMs has not yet outputted a better performing derivative. Bearing this in mind, we now present the synthesis of polymyxin B (PMB) analogues through modification at selected positions, with structurally related uncommon amino acids, considering previous structure-activity relationship studies. The synthesised analogues were evaluated for their antimicrobial activity by determining the minimum inhibitory concentration and minimum bactericidal concentration against planktonic cultures of Gram-negative (P. aeruginosa) and Gram-positive (S. aureus) strains. Their antimicrobial effect was compared with that obtained by the commercial PMB.eng
dc.description.sponsorshipAcknowledgements: the authors acknowledge the funding by FCT - Fundação para a Ciência e a Tecnologia in the scope of project POLYmix-POLYmic (2022.06595.PTDC), the strategic funding to the CQUM (UID/QUI/00686/2020), CEB (UIDB/04469/2020), and LABBELS (LA/P/0029/2020) units.
dc.distributioninternational
dc.identifier.citationLinhares, Mariana; Costa, Susana Paula; Lopes, Susana P., Development of polymyxin B derivatives incorporating uncommon amino acids: synthesis and antimicrobial activity. 7th Meeting on Medicinal Biotechnology & 3rd Iberian Congress on Medicinal Biotechnology. No. P25, Porto, Portugal, May 30, 38, 2025.
dc.identifier.urihttps://hdl.handle.net/1822/98196
dc.language.isoeng
dc.peerreviewedyes
dc.relation2022.06595.PTDC
dc.relationUID/QUI/00686/2020
dc.relationUIDB/04469/2020
dc.relationLA/P/0029/2020
dc.rightsopenAccess
dc.rights.uriN/A
dc.titleDevelopment of polymyxin B derivatives incorporating uncommon amino acids: synthesis and antimicrobial activityeng
dc.typeconferenceAbstract
dspace.entity.typePublicationen
oaire.citationConferencePlacePorto, Portugal
oaire.citationIssueP25
oaire.citationStartPage38
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aa
sdum.conferencePublication7th Meeting on Medicinal Biotechnology & 3rd Iberian Congress on Medicinal Biotechnology

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_58470_1.pdf
Tamanho:
325.36 KB
Formato:
Adobe Portable Document Format